论文部分内容阅读
目的检测癌-睾丸抗原ACTL8和XAGE3在脑肿瘤中的表达,了解其在脑肿瘤中表达的临床意义并讨论其作为脑肿瘤免疫治疗靶抗原的可能性。方法利用逆转录-聚合酶链反应(Reverse Transcription Polymerase Chain Reaction,RT-PCR)方法 ,检测122例脑肿瘤中ACTL8和XAGE3的表达。随机选择ACTL8和XAGE3阳性的RT-PCR产物各2例进行D NA序列测定。结果在122例脑肿瘤中,ACTL8和XAGE3表达率分别为49.18%(60/122),24.59%(30/122);此外,ACTL8和XAGE3还存在联合表达的现象。D NA测序结果表明RT-PCR产物为ACTL8和XAGE3基因。统计学分析显示,在被检测的122例脑肿瘤中,XAGE3和ACTL8的表达除与病理分型有关(P<0.05)外,与其他各项临床指标(性别、年龄、病理分级、卡氏评分)无关联(P>0.05)。结论 ACTL8和XAGE3在脑肿瘤中有一定的表达率,其中XAGE3表达率较高,提示XAGE3可能成为脑肿瘤免疫治疗的靶抗原;而ACTL8和XAGE3的联合表达现象也为提高脑肿瘤的免疫治疗疗效提供了新的思路。
Objective To detect the expression of cancer - testis antigen ACTL8 and XAGE3 in brain tumors and to investigate the clinical significance of their expression in brain tumors and to discuss their potential as target antigens for brain tumor immunotherapy. Methods Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expression of ACTL8 and XAGE3 in 122 cases of brain tumors. Two samples of ACTL8 and XAGE3-positive RT-PCR products were randomly selected for DNA sequence determination. Results In 122 brain tumors, the expression rates of ACTL8 and XAGE3 were 49.18% (60/122) and 24.59% (30/122), respectively. In addition, the expression of ACTL8 and XAGE3 also existed. D NA sequencing results showed that RT-PCR products were ACTL8 and XAGE3 genes. Statistical analysis showed that the expression of XAGE3 and ACTL8 were correlated with other clinical indicators (gender, age, pathological grade, Karnofsky index ) Was not related (P> 0.05). Conclusions ACTL8 and XAGE3 have certain expression rates in brain tumors, and the high expression of XAGE3 suggests that XAGE3 may be the target antigen for brain tumor immunotherapy. The combined expression of ACTL8 and XAGE3 also improves the immunotherapy efficacy of brain tumors Provide a new way of thinking.